Clinical Trial

Evaluation of the Benefit of Lidocaine on the Prevention of the Risk of Post Endoscopic Retrograde Cholangio-pancreatography Pancreatitis.

Study acronym: PEPLID
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 3, 2025 (before its estimated January 18, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is, in a population of patients undergoing ERCP surgery, treated preventively with NSAIDs and divided into two groups according to the absence (group 1) or presence (group 2) of intravenous lidocaine in the general anesthesia protocol. The main objective of this study is to compare the incidence of post-ERCP pancreatitis between the two groups. type of study: clinical trial participant population/health conditions: Patients with ERCP surgery
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-19; most recent amendment 2025-11-25.
Status change: Not Yet Recruiting → Recruiting 2024-06-28
Trial Details
NCT Number NCT05667987
Lead Sponsor GCS Ramsay Santé pour l'Enseignement et la Recherche
Conditions ERCP Surgery
Enrollment 1,800 participants
Start Date 2024-01-18
Primary Completion 2026-01-18 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-03